Introducing the RenovoCath Device
Designed for Targeted Diagnostic & Therapeutic Agent Delivery
Please see the full FDA-cleared intended use statement below.*
About Renovocath
RenovoCath is a patented, FDA-cleared delivery system enabled by an adjustable, dual balloon catheter with intermittent occlusive capabilities. RenovoCath enables physicians to isolate sections of the blood vessel through the adjustment of the distance between the occlusion balloons, thereby excluding any off-target side branches and/or including tumor feeders.
Simplicity
Two-part handle for easy control of balloon distance.
Versatility
Operator controlled adjustable occlusion length.
Delivery
Pressurized catheter enabling targeted delivery of diagnostic or therapeutic agents.
The Potential of RenovoCath: How It Works
Studying The Potential of RenovoCath: How it May Work Outside the Arterial Wall**
Request a demo and learn more
Roges enim Aristonem, bonane ei videantur haec: vacuitas doloris, divitiae, valitudo; Summus dolor plures dies manere non potest.
*RenovoCath is currently cleared for the indication below. The Company is evaluating its novel combination oncology product candidate (intra-arterial gemcitabine, known as IAG) in the ongoing Phase III TIGeR-PaC trial. IAG is being evaluated by the Center for Drug Evaluation and Research (the drug division of FDA) under a U.S. investigational new drug application that is regulated by the FDA’s 21 CFR 312 pathway. Based on completed studies, intra-arterial delivery of chemotherapy via Trans-Arterial Micro-Perfusion (TAMP™), which targets delivery of treatment in proximity to the tumor tissue within the pancreas using the vasa vasorum pathway, reduced tolerability issues associated with systemic chemotherapy and presented early signals of improved patient survival. The study, called TIGeR-PaC (“Intra-Arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC”), and the combination oncology product candidate (IAG) is not yet cleared or approved by FDA for this use and not yet available for commercial sale.
Learn more about RenovoCath and receive updates
Thank you for your interest in the RenovoCath delivery system intended for the isolation of blood flow and delivery of fluids, including diagnostic and/or therapeutic agents, to selected sites in the peripheral vascular system. RenovoCath is also indicated for temporary vessel occlusion in applications including arteriography, preoperative occlusion, and chemotherapeutic drug infusion.
Simply fill in the form and a RenovoRx Associate will follow up with you soon. For the most rapid scheduling, please call 650.284.4433.